Veronica N Anukanga, | |
1427 Good Hope Rd Se, Washington, DC 20020-5614 | |
(202) 836-4841 | |
Not Available |
Full Name | Veronica N Anukanga |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 1427 Good Hope Rd Se, Washington, District Of Columbia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1023712643 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Veronica N Anukanga, 1427 Good Hope Rd Se, Washington, DC 20020-5614 Ph: (202) 836-4841 | Veronica N Anukanga, 1427 Good Hope Rd Se, Washington, DC 20020-5614 Ph: (202) 836-4841 |
News Archive
Just as with computed tomography (CT) and magnetic resonance imaging (MRI), the growth rate among non-radiologists who own or lease positron emission tomography (PET) equipment is also on the rise, contributing significantly to the ongoing issues surrounding self-referral and unnecessary utilization of imaging in the United States, according to a study published in the March issue of the Journal of the American College of Radiology (www.jacr.org)
NextGen Healthcare Information Systems, LLC., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, announced today an agreement with Avita Health System for the deployment of a range of NextGen® solutions across its extensive enterprise.
Palatin Technologies, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs." The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate.
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the detailed results of phase III CLARINET study assessing the effect of Somatuline® Autogel® 120 mg in patients with gastrointestinal and pancreatic neuroendocrine tumors ("GEP-NETs")1 will be disclosed for the first time on September 28, 2013 at the European Cancer Congress 2013 (Sept. 27 - Oct. 1, 2013) in Amsterdam.
How will rapidly expanding health data-intensive technologies affect the future of healthcare work? A team of NYU researchers from the schools of engineering, medicine, and business-led by Professor Oded Nov of NYU Tandon is conducting a broad investigation into how to best bring inclusive tech into the clinic, empowering healthcare workers to take advantage of data-driven research and improve health outcomes for patients.
› Verified 3 days ago